Skip to main content

Ad spending for obesity, diabetes drugs is soaring this year, as drugmakers shell out nearly $500 million

The data demonstrates the rush by companies to capture new customers after months of hype around Novo Nordisk's Ozempic and Wegovy.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.